VANCOUVER, BC — March 5, 2026 — Leads & Copy —
Hydreight Technologies Inc. has announced a strategic investment in Insu Therapeutics Inc., a biopharmaceutical company that is working on a patent-pending buccal drug-delivery platform. This platform is designed to allow for needle-free administration of complex peptide therapeutics, like insulin and GLP-1 receptor agonists, through targeted absorption across the inner cheek, bypassing gastrointestinal degradation pathways.
Insu has finished Phase I in-vitro release and pharmacokinetic studies that evaluated its buccal semaglutide formulation against injectable formats. The company has also received Research Ethics Board approval from the University of British Columbia to begin Phase II studies to assess pharmacokinetics and systemic blood levels in animal models.
Hydreight believes that delivery innovation capable of achieving pharmacokinetic exposure close to injectable formats without needles would be a significant advancement in peptide therapeutics. This is especially true in markets where patient adherence is limited by injection-based delivery.
According to industry research, the global peptide therapeutics market exceeds US$40 billion and is projected to grow at a high single-digit to low double-digit rate over the next decade. Peptide-based therapies are rapidly expanding across metabolic health, obesity, diabetes, hormonal health, longevity medicine, and other chronic conditions. GLP-1 therapies have experienced significant global adoption, contributing to strong demand for patient-friendly delivery formats.
Most peptide therapies remain injection-based because of the difficulty of delivering large peptide molecules orally without degradation or loss of efficacy. As innovation accelerates, delivery has become a primary bottleneck in peptide therapeutics.
Insu Therapeutics is pioneering a patented buccal drug-delivery platform designed to enable the non-injectable administration of complex peptide therapeutics. The platform is intended to improve delivery stability, dosing precision, patient experience, and adherence.
Insu’s buccal tablet platform is engineered to:
- Absorb peptides directly through the inner cheek
- Bypass gastrointestinal degradation
- Avoid first-pass liver metabolism
- Protect active pharmaceutical ingredients from salivary loss
Insu’s semaglutide research uses innovator-manufactured semaglutide and is supported by pharmacokinetic modeling designed to evaluate systemic exposure relative to injection-based administration. The objective is to assess whether buccal delivery can achieve pharmacokinetic profiles comparable to injectable formats while offering a non-invasive dosing alternative for patients.
Dr. Anubhav Pratap-Singh, Inventor of the Buccal Delivery Technology and Scientific Advisor to Insu Therapeutics, said that if buccal delivery can consistently achieve systemic exposure profiles comparable to injectable formats, it has the potential to fundamentally change how complex peptide therapies are administered. He added that their research is focused on evaluating pharmacokinetics and bioavailability to determine whether injection-level performance can be achieved through a non-invasive delivery pathway.
Hydreight’s investment aligns with its strategy of aligning with global intellectual property and differentiated delivery technologies for peptide, hormone, and biologic therapies in consumer-friendly dosage formats that can be scaled through Hydreight’s national VSDHOne platform and pharmacy network.
Shane Madden, Chief Executive Officer of Hydreight, said that Hydreight is building long-term strategic leverage through technology and product alignment. He added that Insu’s delivery approach represents the type of innovation that can potentially reshape how peptide-based therapies are administered.
On March 4, 2026, Hydreight entered into a subscription agreement to acquire 800,000 units of Insu at a price of $0.375 per Unit, for an aggregate investment of $300,000. Each Unit is comprised of one common share of Insu and one common share purchase warrant. Each Warrant entitles the holder to acquire one additional Insu Share at an exercise price of $1.00 per share for a period of two years from issuance. The aggregate consideration for the Units will be satisfied 50% in cash ($150,000) and 50% in common shares of Hydreight (37,037 common shares issued at a deemed price of $4.05 per share).
The transaction remains subject to approval of the TSX Venture Exchange.
Insu recently announced completion of Phase I preclinical studies evaluating in-vitro bioavailability of its proprietary buccal semaglutide tablet compared to injectable semaglutide and has received Research Ethics Board (REB) approval from the University of British Columbia (UBC) to initiate Phase II studies.
Insu has also stated that the semaglutide used in the program is manufactured by Novo Nordisk, the innovator behind Ozempic, with Phase II expected to examine pharmacokinetics, systemic exposure, and performance under chronic administration.
Subject to regulatory approvals and definitive agreements, Hydreight intends to pursue preferred U.S. commercialization rights for peptide products utilizing Insu’s buccal delivery platform through its pharmacy network and the VSDHOne licensee ecosystem.
Hydreight operates:
- A 50-state compliant telehealth network
- A 503A and 503B pharmacy network servicing all 50 states through its Medical Company and Doctor Network
- A network of over 3,000 nurses and over 300+ physicians
- A national licensee base operating through its VSDHOne modular platform
Hydreight’s long-term strategy is to combine infrastructure (telehealth + pharmacy network), distribution (VSDHOne licensees) and proprietary product access. By selectively investing in product innovation and IP, Hydreight seeks to enhance margin control, product exclusivity potential, competitive differentiation and long-term defensibility.
Victory Square Technologies Inc. is a control person of each of the Company and of Insu, and as such, the Company and Insu are Non-Arm’s Length Parties.
Hydreight Technologies Inc. is building one of the largest mobile clinic networks in the United States. Its platform includes a suite of tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables healthcare professionals to provide services directly to patients. Hydreight has a 503A and 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
Developed in partnership with Victory Square Technologies, Hydreight Technologies launched the VSDHOne platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states.
Source: Hydreight Technologies Inc.
